Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD

Detalles Bibliográficos
Autores principales: Schwartz, Jonathan D., Barcellini, Wilma, Grace, Rachel F., Bianchi, Paola, Zanella, Alberto, López Lorenzo, José Luis, Sevilla, Julián, Shah, Ami J., Glader, Bertil, Nicoletti, Eileen, Navarro Ordoñez, Susana, Segovia, José Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Correspondences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305868/
https://www.ncbi.nlm.nih.gov/pubmed/34989415
http://dx.doi.org/10.1002/ajh.26458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305868/
https://www.ncbi.nlm.nih.gov/pubmed/34989415
http://dx.doi.org/10.1002/ajh.26458

Ejemplares similares